Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) activation in acquired hemostatic dysfunction: a diagnostic challenge
- PMID: 21253418
- PMCID: PMC3023042
- DOI: 10.5045/kjh.2010.45.4.215
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) activation in acquired hemostatic dysfunction: a diagnostic challenge
Similar articles
-
Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S69-71. doi: 10.1097/00001721-200306001-00016. Blood Coagul Fibrinolysis. 2003. PMID: 14567541 Review.
-
Stimulation of thrombin- and plasmin-mediated activation of thrombin-activatable fibrinolysis inhibitor by anionic molecules.Thromb Res. 2016 Oct;146:7-14. doi: 10.1016/j.thromres.2016.08.015. Epub 2016 Aug 17. Thromb Res. 2016. PMID: 27564657
-
Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.J Clin Invest. 1997 May 15;99(10):2323-7. doi: 10.1172/JCI119412. J Clin Invest. 1997. PMID: 9153272 Free PMC article.
-
Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?Ann Med. 2006;38(6):378-88. doi: 10.1080/07853890600852898. Ann Med. 2006. PMID: 17008302 Review.
-
Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.Int J Mol Sci. 2021 Apr 1;22(7):3670. doi: 10.3390/ijms22073670. Int J Mol Sci. 2021. PMID: 33916027 Free PMC article. Review.
Cited by
-
Data supporting the structural and functional characterization of Thrombin-Activatable Fibrinolysis Inhibitor in breast cancer.Data Brief. 2015 Nov 14;5:981-9. doi: 10.1016/j.dib.2015.10.043. eCollection 2015 Dec. Data Brief. 2015. PMID: 26740968 Free PMC article.
References
-
- Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477–14484. - PubMed
-
- Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem. 2007;40:431–442. - PubMed
-
- Toh CH. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction. Blood Coagul Fibrinolysis. 2003;14(Suppl 1):S69–S71. - PubMed
-
- Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation. 1996;93:1328–1330. - PubMed
-
- Heylen E, Miljic P, Willemse J, et al. Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. Thromb Res. 2009;124:427–432. - PubMed
LinkOut - more resources
Full Text Sources